Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;179(13):3382-3402.
doi: 10.1111/bph.15812. Epub 2022 Feb 23.

In vivo and cellular antiarrhythmic and cardiac electrophysiological effects of desethylamiodarone in dog cardiac preparations

Zsófia Kohajda  1 , László Virág  2   3 , Tibor Hornyik  2 , Zoltán Husti  2 , Anita Sztojkov-Ivanov  4 , Norbert Nagy  1   2 , András Horváth  2 , Richárd Varga  2 , János Prorok  1   2 , Jozefina Szlovák  2 , Noémi Tóth  2 , Péter Gazdag  2 , Leila Topal  2 , Muhammad Naveed  2 , Tamás Árpádffy-Lovas  2 , Bence Pászti  2 , Tibor Magyar  2 , István Koncz  2 , Szilvia Déri  2 , Vivien Demeter-Haludka  2 , Zoltán Aigner  5 , Balázs Ördög  2 , Márta Patfalusi  6 , László Tálosi  7 , László Tiszlavicz  8 , Imre Földesi  9 , Norbert Jost  1   2   3 , István Baczkó  2   3 , András Varró  1   2   3
Affiliations
Free article

In vivo and cellular antiarrhythmic and cardiac electrophysiological effects of desethylamiodarone in dog cardiac preparations

Zsófia Kohajda et al. Br J Pharmacol. 2022 Jul.
Free article

Abstract

Background and purpose: The aim of the present study was to study the antiarrhythmic effects and cellular mechanisms of desethylamiodarone (DEA), the main metabolite of amiodarone (AMIO), following acute and chronic 4-week oral treatments (25-50 mg·kg-1 ·day-1 ).

Experimental approach: The antiarrhythmic effects of acute iv. (10 mg·kg-1 ) and chronic oral (4 weeks, 25 mg·kg-1 ·day-1 ) administration of DEA were assessed in carbachol and tachypacing-induced dog atrial fibrillation models. Action potentials were recorded from atrial and right ventricular tissue following acute (10 μM) and chronic (p.o. 4 weeks, 50 mg·kg-1 ·day-1 ) DEA application using the conventional microelectrode technique. Ionic currents were measured by the whole cell configuration of the patch clamp technique in isolated left ventricular myocytes. Pharmacokinetic studies were performed following a single intravenous dose (25 mg·kg-1 ) of AMIO and DEA intravenously and orally. In chronic (91-day) toxicological investigations, DEA and AMIO were administered in the oral dose of 25 mg·kg-1 ·day-1 ).

Key results: DEA exerted marked antiarrhythmic effects in both canine atrial fibrillation models. Both acute and chronic DEA administration prolonged action potential duration in atrial and ventricular muscle without any changes detected in Purkinje fibres. DEA decreased the amplitude of several outward potassium currents such as IKr , IKs , IK1 , Ito , and IKACh , while the ICaL and late INa inward currents were also significantly depressed. Better drug bioavailability and higher volume of distribution for DEA were observed compared to AMIO. No neutropenia and less severe pulmonary fibrosis was found following DEA compared to that of AMIO administration.

Conclusion and implications: Chronic DEA treatment in animal experiments has marked antiarrhythmic and electrophysiological effects with better pharmacokinetics and lower toxicity than its parent compound. These results suggest that the active metabolite, DEA, should be considered for clinical trials as a possible new, more favourable option for the treatment of cardiac arrhythmias including atrial fibrillation.

Keywords: atrial fibrillation; canine; cardiac electrophysiology; desethylamiodarone.

PubMed Disclaimer

References

REFERENCES

    1. Adams, P. C., Holt, D. W., Storey, G. C., Morley, A. R., Callaghan, J., & Campbell, R. W. (1985). Amiodarone and its desethyl metabolite: Tissue distribution and morphologic changes during long-term therapy. Circulation, 72(5), 1064-1075. https://doi.org/10.1161/01.CIR.72.5.1064
    1. Alexander, S. P., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Aldrich, R. W., Attali, B., Baggetta, A. M., Becirovic, E., Biel, M., Bill, R. M., Catterall, W. A., … Zhu, M. (2021). The concise guide to pharmacology 2021/22: Ion channels. British Journal of Pharmacology, 178(S1), S157-S245.
    1. Árpádffy-Lovas, T., Baczkó, I., Baláti, B., Bitay, M., Jost, N., Lengyel, C., Nagy, N., Takács, J., Varró, A., & Virág, L. (2020). Electrical restitution and its modifications by antiarrhythmic drugs in undiseased human ventricular muscle. Frontiers in Pharmacology, 11, 479. https://doi.org/10.3389/fphar.2020.00479
    1. Baczko, I., Liknes, D., Yang, W., Hamming, K. C., Searle, G., Jaeger, K., Husti, Z., Juhasz, V., Klausz, G., Pap, R., Saghy, L., Varro, A., Dolinsky, V., Wang, S., Rauniyar, V., Hall, D., Dyck, J. R. B., & Light, P. E. (2014). Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation. British Journal of Pharmacology, 171(1), 92-106. https://doi.org/10.1111/bph.12409
    1. Bolderman, R. W., Hermans, J. J. R., & Maessen, J. G. (2009). Determination of the class III antiarrhythmic drugs dronedarone and amiodarone, and their principal metabolites in plasma and myocardium by high-performance liquid chromatography and UV-detection. Journal of Chromatography B, 877, 1727-1731. https://doi.org/10.1016/j.jchromb.2009.04.029

Publication types

LinkOut - more resources